The top common differential m6A regulator, IGF2BP2 (also known as IMP2, a m6A Reader), is a direct mTOR substrate that participates in glucose, lipid, protein, and energy metabolism (Dai, 2020), which are key events in the pathogenesis of IBD (Lloyd-Price et al., 2019; Ding et al., 2020). Here, IGF2BP2 is linked to inflammatory bowel disease.